Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

162 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines.
Proto C, Manglaviti S, Lo Russo G, Musca M, Galli G, Imbimbo M, Perrino M, Cordua N, Rulli E, Ballatore Z, Maso AD, Chella A, Sbrana A, Prelaj A, Ferrara R, Occhipinti M, Brambilla M, De Toma A, Mazzeo L, Beninato T, Signorelli D, Massa G, Greco FG, Calareso G, Miliziano D, Di Mauro RM, Mella G, Lucarelli A, Paggio A, Galli F, Torri V, de Braud FGM, Pasello G, Petrini I, Berardi R, Ganzinelli M, Garassino MC, Zucali PA. Proto C, et al. Among authors: zucali pa. J Thorac Oncol. 2023 Aug;18(8):1070-1081. doi: 10.1016/j.jtho.2023.04.009. Epub 2023 Apr 23. J Thorac Oncol. 2023. PMID: 37094664 Clinical Trial.
Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients.
Lemos C, Giovannetti E, Zucali PA, Assaraf YG, Scheffer GL, van der Straaten T, D'Incecco A, Falcone A, Guchelaar HJ, Danesi R, Santoro A, Giaccone G, Tibaldi C, Peters GJ. Lemos C, et al. Among authors: zucali pa. Pharmacogenomics. 2011 Feb;12(2):159-70. doi: 10.2217/pgs.10.172. Pharmacogenomics. 2011. PMID: 21332310 Free PMC article.
Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin.
Giovannetti E, Zucali PA, Assaraf YG, Leon LG, Smid K, Alecci C, Giancola F, Destro A, Gianoncelli L, Lorenzi E, Roncalli M, Santoro A, Peters GJ. Giovannetti E, et al. Among authors: zucali pa. Br J Cancer. 2011 Nov 8;105(10):1542-53. doi: 10.1038/bjc.2011.400. Epub 2011 Oct 4. Br J Cancer. 2011. PMID: 21970874 Free PMC article.
Is gemcitabine cost effective in cancer treatment?
Toschi L, Finocchiaro G, Ceresoli GL, Zucali PA, Cavina R, Garassino I, De Vincenzo F, Santoro A, Cappuzzo F. Toschi L, et al. Among authors: zucali pa. Expert Rev Pharmacoecon Outcomes Res. 2007 Jun;7(3):239-49. doi: 10.1586/14737167.7.3.239. Expert Rev Pharmacoecon Outcomes Res. 2007. PMID: 20528311
Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib.
Giovannetti E, Zucali PA, Peters GJ, Cortesi F, D'Incecco A, Smit EF, Falcone A, Burgers JA, Santoro A, Danesi R, Giaccone G, Tibaldi C. Giovannetti E, et al. Among authors: zucali pa. Mol Cancer Ther. 2010 Mar;9(3):581-93. doi: 10.1158/1535-7163.MCT-09-0665. Epub 2010 Feb 16. Mol Cancer Ther. 2010. PMID: 20159991 Free article.
Anti-angiogenic therapies for malignant pleural mesothelioma.
Ceresoli GL, Zucali PA. Ceresoli GL, et al. Among authors: zucali pa. Expert Opin Investig Drugs. 2012 Jun;21(6):833-44. doi: 10.1517/13543784.2012.681641. Epub 2012 Apr 23. Expert Opin Investig Drugs. 2012. PMID: 22519641 Review.
162 results